Parkinson Disease
Conditions
Brief summary
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.
Detailed description
This is a randomized, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory of tesofensine versus placebo in levodopa treated Parkinson patients with motor fluctuations. Patients will be treated either with one of the 4 doses of tesofensine (0.125mg, 0.25mg, 0.50 mg or 1.0 mg) or with placebo, once daily, over 14 weeks. The two co-primary efficacy endpoints are the change in off-time and the change in the Unified Parkinson Disease Rating Scale (UPDRS) II+III total score Study Hypothesis: The null hypothesis is that there is no difference between placebo and tesofensine. The alternative hypothesis is that treatment with tesofensine is superior to treatment with placebo. Comparison(s): For the primary comparison between tesofensine and placebo, change in percentage off-time during waking hours will be based on reports from patient's diary (completed at day -3 and day-2 prior to the study visits) and change in the UPDRS II+III will be based on UPDRS II averaged for on and off periods and UPDRS III evaluated at on periods during the study visits.
Interventions
DRUG1. Tesofensine (NS 2330)
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
42 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Main inclusion criteria: * Male or female patient with idiopathic Parkinson Disease (PD) diagnosed for at least 2 years. * Patient aged 40 years or over at time of diagnosis of PD and not older than 80 years at screening visit. * Modified Hoehn and Yahr stage of II to III at on time. * Treatment with Levodopa at an optimised dose, 4 to 8 times per day, this dose being stable for at least 4 weeks prior to screening visit. * Motor fluctuations, with 2.0 to 6.0 cumulative hours of off time every day during waking hours, documented from patient's diary completed for 2 consecutive days before baseline visit. Main
Exclusion criteria
* Neuropsychiatric exclusions: Non-idiopathic PD, dementia (Mini Mental State Exam \<26), history of psychosis, history or current Axis I or Axis II mental disorder according to DSM-IV, etc * Other medical exclusions, like ECG abnormalities, hypotension and/or symptomatic orthostatic hypotension, some abnormal laboratory parameters (e.g. severe renal impairment), etc * Pharmacological exclusions, e.g. selegiline within 8 weeks prior to screening visit, regular use of anti-depressant drugs, any medication with central dopaminergic antagonist activity, etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UPDRS parts II (averaged on and off) | 14 weeks |
| Off time during waking hours | 14 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impressions (CGI) Improvement and Severity | 14 weeks |
| Auditory Verbal Learning test (AVLT) | 14 weeks |
| Modified Schwab and England Disability scale | 14 weeks |
| Percent on time without dyskinesia, or with non troublesome dyskinesia, or both, or with troublesome dyskinesia | 14 weeks |
| Percentage of patients with at least a 20%-improvement in percent off time during waking hours | 14 weeks |
| Percentage of patients with at least a 20% or a 30%-improvement in UPDRS parts II+III total score | 14 weeks |
| Snaith-Hamilton Pleasure Scale (SHAPS) | 14 weeks |
| Unified Parkinson's Disease Rating Scale (UPDRS) I to IV sub-scores | 14 weeks |
Countries
Austria, France, Germany, Netherlands, Spain, United Kingdom
Outcome results
None listed